title: [Study on retreatment of CHC patients with initial treatment failure].
abstract: OBJECTIVE
  To explore the retreatment of CHC patients with initial treatment failure and how to achieve SVR.
  
  
  METHODS
  54 patients who had experienced treatment failure were enrolled and retreated with standard treatment of pegylated interferon and ribavirin or intensive treatment, respectively. Their SVR rates were statistically compared, to decide two therapies' application.
  
  
  RESULTS
  54 patients had been retreated, and total SVR rate was up to 75.92%, with 88.46% in relapsed patients and 64.29% in non-responders. After retreatment with pegylated interferon and ribavirin, SVR rate was 95.45% in patients with prior interferon monotherapy, and 64.71% in patients with prior interferon and ribavirin, and 60% in patients with prior pegylated interferon alpha-2a monotherapy. SVR rate of relapsed patients was significantly higher than that of non-responders.
  
  
  CONCLUSIONS
  In CHC patients with treatment failure, SVR rate of retreatment with standard treatment or intensive treatment still can be up to 60%-90%. Retreatment with standard therapy can be applied to patients who had received interferon monotherapy or interferon plus ribavirin. Three types of patients who need intensive retreatment were as following: patients nonresponsive to interferon plus ribavirin or pegylated interferon alpha-2a monotherapy, and patients with treatment failure who had received prior standard treatment.
authors.affiliation: Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Zhang
authors.forename: Ge
authors.initials: G
authors.lastname: Shen
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Zhang
authors.forename: Guo-Hua
authors.initials: GH
authors.lastname: Qiu
authors.forename: Yao
authors.initials: Y
authors.lastname: Lu
authors.forename: Hui
authors.initials: H
authors.lastname: Zhao
authors.forename: Min
authors.initials: M
authors.lastname: Yang
authors.forename: Ming-Hui
authors.initials: MH
authors.lastname: Li
authors.forename: Yao
authors.initials: Y
authors.lastname: Xie
authors.forename: Jun
authors.initials: J
authors.lastname: Cheng
authors.forename: Dao-Zhen
authors.initials: DZ
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D019233:Retreatment; D012254:Ribavirin / Q000627:therapeutic use; D017211:Treatment Failure; D019562:Viral Load / Q000187:drug effects; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a